{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05975983",
            "orgStudyIdInfo": {
                "id": "INS018-055-004"
            },
            "organization": {
                "fullName": "InSilico Medicine Hong Kong Limited",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis",
            "officialTitle": "A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)",
            "therapeuticArea": [
                "Respiratory"
            ],
            "study": "study-evaluating-administered-orally-to-subjects-with-idiopathic-pulmonary-fibrosis"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-02-08",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-02-28",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-02-28",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-07-27",
            "studyFirstSubmitQcDate": "2023-07-27",
            "studyFirstPostDateStruct": {
                "date": "2023-08-04",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-25",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "InSilico Medicine Hong Kong Limited",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this clinical trial is to learn about INS018_055 in adults with Idiopathic Pulmonary Fibrosis (IPF).\n\nThe primary objective is to evaluate the safety and tolerability of INS018_055 orally administered for up to 12 weeks in adult subjects with IPF compared to placebo."
        },
        "conditionsModule": {
            "conditions": [
                "Idiopathic Pulmonary Fibrosis (IPF)"
            ],
            "keywords": [
                "Pulmonary Fibrosis",
                "Idiopathic Pulmonary Fibrosis",
                "Fibrosis",
                "Pathologic Processes",
                "Lung Diseases, Interstitial",
                "Lung Diseases",
                "Respiratory Tract Diseases"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 60,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "INS018_055",
                    "type": "EXPERIMENTAL",
                    "description": "Group 1: INS018_055 once daily up to 12 weeks, low dose\n\nGroup 2: INS018_055 twice daily up to 12 weeks, low dose\n\nGroup 3: INS018_055 once daily up to 12 weeks, high dose",
                    "interventionNames": [
                        "Drug: INS018_055"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Group 4: Placebo once or twice daily up to 12 weeks",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "INS018_055",
                    "description": "Pharmaceutical formulation: Capsules\n\nMode of Administration: Oral",
                    "armGroupLabels": [
                        "INS018_055"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Pharmaceutical formulation: Capsules\n\nMode of Administration: Oral",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Percentage of patients who have at least 1 treatment-emergent adverse event (TEAE)",
                    "timeFrame": "Day 1 (Visit 2) up to Week 12 (End of Treatment (EOT))"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Maximum plasma concentration (Cmax) of INS018_055 and metabolites (INS018_063 and INS018_095)",
                    "timeFrame": "Following the first dose on Day 1 (Visit 2) and the last dose during Week 12 (Visit 6, End of Treatment (EOT))"
                },
                {
                    "measure": "Time at which the maximum plasma concentration occurred (tmax) of INS018_055 and metabolites (INS018_063 and INS018_095)",
                    "timeFrame": "Following the first dose on Day 1 (Visit 2) and the last dose during Week 12 (Visit 6, End of Treatment (EOT))"
                },
                {
                    "measure": "Area under the plasma concentration-time curve from time zero to dosing interval \u03c4 (AUC0-\u03c4) of INS018_055 and metabolites (INS018_063 and INS018_095)",
                    "timeFrame": "Following the first dose on Day 1 (Visit 2) and the last dose during Week 12 (Visit 6, End of Treatment (EOT))"
                },
                {
                    "measure": "Area under the plasma concentration-time curve from time zero to time with last measurable concentration t (AUC0-t) of INS018_055 and metabolites (INS018_063 and INS018_095)",
                    "timeFrame": "Following the first dose on Day 1 (Visit 2) and the last dose during Week 12 (Visit 6, End of Treatment (EOT))"
                },
                {
                    "measure": "Area under the plasma concentration-time curve from time zero to infinity (\u221e) (AUC0-\u221e) of INS018_055 and metabolites (INS018_063 and INS018_095)",
                    "timeFrame": "Following the first dose on Day 1 (Visit 2) and the last dose during Week 12 (Visit 6, End of Treatment (EOT))"
                },
                {
                    "measure": "Terminal elimination half-life (t1/2) of INS018_055 and metabolites (INS018_063 and INS018_095)",
                    "timeFrame": "Following the first dose on Day 1 (Visit 2) and the last dose during Week 12 (Visit 6, End of Treatment (EOT))"
                },
                {
                    "measure": "Terminal elimination rate constant (\u03bbz) of INS018_055 and metabolites (INS018_063 and INS018_095)",
                    "timeFrame": "Following the first dose on Day 1 (Visit 2) and the last dose during Week 12 (Visit 6, End of Treatment (EOT))"
                },
                {
                    "measure": "Apparent clearance (CL/F) of INS018_055 and metabolites (INS018_063 and INS018_095)",
                    "timeFrame": "Following the first dose on Day 1 (Visit 2) and the last dose during Week 12 (Visit 6, End of Treatment (EOT))"
                },
                {
                    "measure": "Apparent volume of distribution (Vz/F) of INS018_055 and metabolites (INS018_063 and INS018_095)",
                    "timeFrame": "Following the first dose on Day 1 (Visit 2) and the last dose during Week 12 (Visit 6, End of Treatment (EOT))"
                },
                {
                    "measure": "Accumulation ratio (Rac) for Cmax and AUC of INS018_055 and metabolites (INS018_063 and INS018_095)",
                    "timeFrame": "Following the first dose on Day 1 (Visit 2) and the last dose during Week 12 (Visit 6, End of Treatment (EOT))"
                },
                {
                    "measure": "Trough plasma concentration (Ctrough) of INS018_055 and metabolites (INS018_063 and INS018_095)",
                    "timeFrame": "Following the first dose on Day 1 (Visit 2) and the last dose during Week 12 (Visit 6, End of Treatment (EOT))"
                },
                {
                    "measure": "Relative change in Forced Vital Capacity (FVC) in mL",
                    "timeFrame": "Week 0/Visit 2 up to Week 12"
                },
                {
                    "measure": "Percentage change in FVC in mL",
                    "timeFrame": "Week 0/Visit 2 up to Week 12"
                },
                {
                    "measure": "Absolute and relative change in FVC % predicted",
                    "timeFrame": "Week 0/Visit 2 up to Week 12"
                },
                {
                    "measure": "Change in Diffusion Capacity of the lung for Carbon Monoxide (DLCO) % predicted",
                    "timeFrame": "Week 0/Visit 2 to Week 12"
                },
                {
                    "measure": "Change in Leicester Cough Questionnaire (LCQ)",
                    "timeFrame": "Week 0 to Week 4, 8 and 12"
                },
                {
                    "measure": "Change in 6-Minute Walk Distance (6MWD) in meters",
                    "timeFrame": "Week 0 to Week 12"
                },
                {
                    "measure": "Number of acute IPF exacerbations",
                    "timeFrame": "Week 0 up to Week 12"
                },
                {
                    "measure": "Number of days hospitalized for acute IPF exacerbations",
                    "timeFrame": "Week 0 to up Week 12"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Male or female patients aged \u226540 years based on the date of the written informed consent form\n2. Diagnosis of IPF as defined by American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guidelines\n3. In a stable condition and suitable for study participation based on the results of medical history, physical examination, vital signs, 12-lead ECG, and laboratory evaluation\n4. Subjects with background pirfenidone or nintedanib may be enrolled if their regimen of antifibrotic therapy has been stable for \u2265 8 weeks prior to Visit 1\n\nMeeting all of the following criteria during the screening period:\n\n1. FVC \u226540% predicted of normal\n2. DLCO corrected for Hgb \u226525% and \\<80% predicted of normal.\n3. forced expiratory volume in the first second/FVC (FEV1/FVC) ratio \\>0.7 based on pre-bronchodilator value\n\nExclusion Criteria:\n\n1. Acute IPF exacerbation within 4 months prior to Visit 1 and/or Day 1, as determined by the investigator\n2. Patients who are unwilling to refrain from smoking within 3 months prior to screening and until the end of the study\n3. Female patients who are pregnant or nursing\n4. Abnormal ECG findings",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "40 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Yichen Liu",
                    "role": "CONTACT",
                    "phone": "+86 18817554306",
                    "email": "Insilico-Clinicaltrial@insilico.ai"
                },
                {
                    "name": "Franz Espiritu",
                    "role": "CONTACT",
                    "email": "franz@insilicomedicine.com"
                }
            ],
            "locations": [
                {
                    "facility": "Keck School of Medicine of USC",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90033",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Florida Lung Asthma and Sleep Specialist",
                    "status": "RECRUITING",
                    "city": "Celebration",
                    "state": "Florida",
                    "zip": "34747-1818",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.32529,
                        "lon": -81.53313
                    }
                },
                {
                    "facility": "Central Florida Pulmonary Group, P.A. (CFPG) - Downtown Orlando",
                    "status": "RECRUITING",
                    "city": "Orlando",
                    "state": "Florida",
                    "zip": "32803-5727",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.53834,
                        "lon": -81.37924
                    }
                },
                {
                    "facility": "Southeastern Research Center",
                    "status": "RECRUITING",
                    "city": "Winston-Salem",
                    "state": "North Carolina",
                    "zip": "27103-4007",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.09986,
                        "lon": -80.24422
                    }
                },
                {
                    "facility": "University of Oklahoma Health Sciences Center (OUHSC)",
                    "status": "RECRUITING",
                    "city": "Oklahoma City",
                    "state": "Oklahoma",
                    "zip": "73104-5417",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.46756,
                        "lon": -97.51643
                    }
                },
                {
                    "facility": "Bogan Sleep Consultants, LLC",
                    "status": "RECRUITING",
                    "city": "Columbia",
                    "state": "South Carolina",
                    "zip": "29201-2953",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.00071,
                        "lon": -81.03481
                    }
                },
                {
                    "facility": "University of Texas Southwestern Medical Center",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75235-6243",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "Metroplex Pulmonary and Sleep Center",
                    "status": "RECRUITING",
                    "city": "McKinney",
                    "state": "Texas",
                    "zip": "75069-1898",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.19762,
                        "lon": -96.61527
                    }
                },
                {
                    "facility": "Research Centers of America",
                    "status": "RECRUITING",
                    "city": "McKinney",
                    "state": "Texas",
                    "zip": "75071",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.19762,
                        "lon": -96.61527
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011658",
                    "term": "Pulmonary Fibrosis"
                },
                {
                    "id": "D000054990",
                    "term": "Idiopathic Pulmonary Fibrosis"
                },
                {
                    "id": "D000005355",
                    "term": "Fibrosis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000017563",
                    "term": "Lung Diseases, Interstitial"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14512",
                    "name": "Pulmonary Fibrosis",
                    "asFound": "Pulmonary Fibrosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19813",
                    "name": "Lung Diseases, Interstitial",
                    "relevance": "LOW"
                },
                {
                    "id": "M8485",
                    "name": "Fibrosis",
                    "asFound": "Fibrosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27989",
                    "name": "Idiopathic Pulmonary Fibrosis",
                    "asFound": "Idiopathic Pulmonary Fibrosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3003",
                    "name": "Idiopathic Pulmonary Fibrosis",
                    "asFound": "Idiopathic Pulmonary Fibrosis",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}